

May 1, 2019



# **Adaptimmune to Provide Clinical and Business Update on Monday May 6th, 2019**

PHILADELPHIA and OXFORDSHIRE, United Kingdom, May 01, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will provide a clinical and business update before the U.S. markets open on Monday May 6, 2019. Following the announcement, the Company will host a live teleconference and webcast with accompanying slides at 8:00 a.m. EDT (1:00 p.m. BST) on the same day (details below).

## **Conference Call and Webcast Link for Clinical and Business Update Slide Presentation on May 6<sup>th</sup>**

The Company will host a live teleconference and slide presentation at 8:00 a.m. EDT (1:00 p.m. BST) on Monday May 6, 2019. The live webcast of the conference call and slides will be available at <https://edge.media-server.com/m6/p/pfkkjdm4>. An archive will be available after the call at the same address. To participate in the live webinar, if preferred, please dial (833) 652-5917 (U.S. and Canada) or +1 (430) 775-1624 (International).

## **About Adaptimmune**

Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for cancer patients. The Company's unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors. For more information, please visit <http://www.adaptimmune.com>.

## **Forward-Looking Statements**

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 27, 2019, and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.

## **Adaptimmune Contacts:**

## **Media Relations:**

Sébastien Desprez – VP, Communications and Investor Relations

T: +44 1235 430 583

M: +44 7718 453 176

[Sebastien.Desprez@adaptimmune.com](mailto:Sebastien.Desprez@adaptimmune.com)

**Investor Relations:**

Juli P. Miller, Ph.D. – Senior Director, Investor Relations

T: +1 215 825 9310

M: +1 215 460 8920

[Juli.Miller@adaptimmune.com](mailto:Juli.Miller@adaptimmune.com)



Source: Adaptimmune Therapeutics plc